Navigation Links
InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
Date:2/13/2009

BRISBANE, Calif., Feb. 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock. The last reported sale price of InterMune's common stock on the NASDAQ Global Select Market on February 12, 2009 was $17.96. The offering is expected to close on or about February 19, 2009, subject to customary closing conditions. All of the shares are being sold by the company.

UBS Investment Bank is the sole manager for the offering. InterMune has granted the underwriter a 30-day option to purchase up to an additional 525,000 shares to cover over-allotments, if any.

A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission.

A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the Securities and Exchange Commission. When available, copies of the prospectus supplement and the accompanying prospectus may be obtained from

                                 UBS Investment Bank
                             ATTN: Prospectus Department
                                   299 Park Avenue
                                  New York, NY 10171
                       or by telephone toll free at 888-827-7275.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of InterMune's common stock, nor shall there be any sale of such common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About InterMune

InterMune is a biotechnology company focused on the research,
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... ISIS ) announces the following webcast: , , ... of a, microRNA, ... 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT, Where: ... Simply log onto our website listed above., , ...
... in the research of vein treatment methods led by Dr. Sinjae Hyun, ... new medical device, which he will present this summer to his research ... ... A gift from a California company aided in the research of ...
... Dec. 1 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... and Drug,Administration (FDA) has accepted for filing and ... supplemental Biologics License Application,(sBLA) for use of Zevalin(R) ... B-cell non-Hodgkin,s lymphoma who achieve,a response to first-line ...
Cached Biology Technology:Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... search for better ways to target anticancer drugs to ... nanoparticles called buckyballs might be used to significantly boost ... In research due to appear in an upcoming issue ... and The University of Texas M. D. Anderson Cancer ...
... the National Institute of Standards and Technology (NIST) have ... for small numbers of biomolecules. The unusually simple containment ... and perhaps lead to the development of molecule-sorting devices ... research. The work was reported in the July 3 ...
... world soon could be made completely flood-tolerant because ... in collaboration with scientists at UC Davis and ... By gradually introducing into California rice "submergence tolerance," ... flood conditions, the researchers show how potentially any ...
Cached Biology News:Buckyballs boost antibody's chemotherapy payload 2'Micro-boxes' of water used to study single molecules 2Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3
... The potential applications for the use of ... gene expression via the RNA interference (RNAi) ... cellular and molecular biology fields. siRNA for ... either chemically or enzymatically, and then transfected ...
... applications for the use of small interfering ... via the RNA interference,(RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... and then transfected into the target cells ...
... HybArray 12™ is an automated hybridization system ... system automates both the hybridization and post ... slides. A single instrument can process up ... pairs and has multi-protocol software, enabling the ...
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
Biology Products: